Cannara Biotech Inc. (TSXV:LOVE)
Canada
· Delayed Price · Currency is CAD 1.290
+0.040 (3.20%)
Feb 21, 2025, 3:55 PM EST
Cannara Biotech Income Statement
Financials in millions CAD. Fiscal year is September - August.
Millions CAD. Fiscal year is Sep - Aug.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Nov '24 Nov 30, 2024 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 | Aug '20 Aug 31, 2020 | 2019 - 2018 |
| Operating Revenue | 87.18 | 81.65 | 57.07 | 35.48 | 16.29 | 2.47 | Upgrade
|
| Other Revenue | 0.09 | 0.09 | 0.19 | 0.36 | 0.73 | 0.08 | Upgrade
|
| Revenue | 87.28 | 81.75 | 57.26 | 35.84 | 17.02 | 2.55 | Upgrade
|
| Revenue Growth (YoY) | 31.35% | 42.77% | 59.76% | 110.58% | 567.24% | 21.64% | Upgrade
|
| Cost of Revenue | 55.6 | 51.96 | 30.03 | 18.51 | 6.72 | 1.33 | Upgrade
|
| Gross Profit | 31.67 | 29.79 | 27.23 | 17.33 | 10.3 | 1.22 | Upgrade
|
| Selling, General & Admin | 18.95 | 17.67 | 11.77 | 9.68 | 6.98 | 8.23 | Upgrade
|
| Research & Development | 1.08 | 1.12 | 1.03 | 1.26 | 1.91 | 2.6 | Upgrade
|
| Operating Expenses | 23.3 | 22.14 | 15.51 | 12.51 | 10.24 | 13.18 | Upgrade
|
| Operating Income | 8.37 | 7.64 | 11.72 | 4.82 | 0.05 | -11.96 | Upgrade
|
| Interest Expense | -4.9 | -5.05 | -4.74 | -2.23 | -1.71 | -1.35 | Upgrade
|
| Interest & Investment Income | 0.18 | 0.18 | 0.24 | 0.09 | 0.05 | 0.27 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.13 | -0.12 | 0.07 | 0.03 | -0.11 | -0.04 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.57 | -0.61 | -0.56 | -0.53 | -0.02 | -0.01 | Upgrade
|
| EBT Excluding Unusual Items | 2.96 | 2.04 | 6.72 | 2.18 | -1.73 | -13.1 | Upgrade
|
| Gain (Loss) on Sale of Assets | 2.04 | 2.03 | -0.13 | -0.05 | -0.07 | -0.01 | Upgrade
|
| Asset Writedown | - | - | - | - | - | -0.04 | Upgrade
|
| Other Unusual Items | 0.41 | 0.41 | 0.36 | 0.17 | 0.27 | 0.05 | Upgrade
|
| Pretax Income | 5.41 | 4.48 | 6.95 | 2.31 | -1.53 | -13.09 | Upgrade
|
| Income Tax Expense | -1.23 | -1.95 | - | - | - | - | Upgrade
|
| Earnings From Continuing Operations | 6.64 | 6.44 | 6.95 | 2.31 | -1.53 | -13.09 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | - | 0.61 | Upgrade
|
| Net Income | 6.64 | 6.44 | 6.95 | 2.31 | -1.53 | -12.48 | Upgrade
|
| Net Income to Common | 6.64 | 6.44 | 6.95 | 2.31 | -1.53 | -12.48 | Upgrade
|
| Net Income Growth | -26.66% | -7.30% | 201.26% | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 90 | 90 | 89 | 88 | 77 | 71 | Upgrade
|
| Shares Outstanding (Diluted) | 92 | 91 | 90 | 88 | 77 | 71 | Upgrade
|
| Shares Change (YoY) | 1.10% | 1.83% | 2.16% | 14.80% | 7.26% | 16.02% | Upgrade
|
| EPS (Basic) | 0.07 | 0.07 | 0.08 | 0.03 | -0.02 | -0.17 | Upgrade
|
| EPS (Diluted) | 0.07 | 0.07 | 0.08 | 0.03 | -0.10 | -0.17 | Upgrade
|
| EPS Growth | -25.80% | -10.00% | 195.77% | - | - | - | Upgrade
|
| Free Cash Flow | 9.82 | 3.21 | -3.97 | -21.55 | -33.17 | -18.51 | Upgrade
|
| Free Cash Flow Per Share | 0.11 | 0.04 | -0.04 | -0.25 | -0.43 | -0.26 | Upgrade
|
| Gross Margin | 36.29% | 36.44% | 47.56% | 48.36% | 60.49% | 48.00% | Upgrade
|
| Operating Margin | 9.59% | 9.35% | 20.46% | 13.45% | 0.31% | -468.76% | Upgrade
|
| Profit Margin | 7.60% | 7.88% | 12.13% | 6.43% | -8.98% | -489.35% | Upgrade
|
| Free Cash Flow Margin | 11.25% | 3.93% | -6.93% | -60.11% | -194.86% | -725.49% | Upgrade
|
| EBITDA | 14.39 | 13.74 | 16.53 | 8.62 | 2.75 | -9.72 | Upgrade
|
| EBITDA Margin | 16.49% | 16.81% | 28.87% | 24.06% | 16.18% | - | Upgrade
|
| D&A For EBITDA | 6.02 | 6.1 | 4.82 | 3.8 | 2.7 | 2.24 | Upgrade
|
| EBIT | 8.37 | 7.64 | 11.72 | 4.82 | 0.05 | -11.96 | Upgrade
|
| EBIT Margin | 9.59% | 9.35% | 20.46% | 13.45% | 0.31% | - | Upgrade
|
| Revenue as Reported | 87.74 | 82.15 | 57.56 | 36 | 17.27 | 2.58 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.